CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Autor: Brown, Jennifer R. 1, Hillmen, Peter 2, Eichhorst, Barbara 3, Lamanna, Nicole 4, O'Brien, Susan 5, Tam, Constantine S. 6, 7, 8, 9, Qiu, Lugui 10, Kazmierczak, Maciej 11, Zhou, Keshu 12, Šimkovič, Martin 13, 14, Mayer, Jiri 15, Gillespie-Twardy, Amanda 16, Shadman, Mazyar 17, 18, Ferrajoli, Alessandra 19, Ganly, Peter S. 20, 21, Weinkove, Robert 22, 23, Salmi, Tommi 24, Wu, Kenneth 24, Novotny, William 24, Jurczak, Wojciech 25
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S266-S266
Databáze: ScienceDirect
Externí odkaz: